Safety and effectiveness of LORLAtinib as a FIRST-line treatment in an ALK-positive Advanced Non-Small Cell Lung Cancer Spanish population. (LORLA-FIRST).

Study identification

• EU PAS number:
  EUPAS1000000406
• Study ID:
  1000000406
• Official title and acronym:
  Safety and effectiveness of LORLAtinib as a FIRST-line treatment in an ALK-positive Advanced Non-Small Cell Lung Cancer Spanish population. (LORLA-FIRST).
• DARWIN EU® study:
  No
• Study countries:
  Spain
• Study description:
  The study is an observational, non-interventional, prospective and multicenter trial that evaluate the real world safety and effectiveness of lorlatinib as a first-line treatment in patients with ALK-positive non-small cell lung cancer (NSCLC) in Spain.
• Study status:
  Planned

Research institutions and networks

Institutions

Pfizer

Study timelines

Date when funding contract was signed

Planned: 20/11/2024

Actual: 20/11/2024

Study start date

Planned: 01/06/2025

Date of final study report

Planned: 31/05/2028

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

B7461054